Skip to main content

Table 1 Summary of patient demographics for the OCEAN population, by indication

From: Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

Primary indication N Age mean ± SD (years) Gender, n (%) BMI mean ± SD (kg/m2) Time since diagnosis of primary indication mean ± SD (years)a Baseline VA
male female ETDRS letters analogue (mean ± SD)
Overallb 5606 74.6 ± 10.3 2451 (43.72) 3136 (55.94) 27.3 ± 4.5 0.56 ± 1.38 53.9 ± 20.6
nAMDc 3614 77.9 ± 8.2 1393 (38.5) 2210 (61.2) 26.6 ± 4.0 0.53 ± 1.28 52.0 ± 21.3
DMEd 1211 67.6 ± 10.9 698 (57.6) 507 (41.9) 29.3 ± 5.2 0.68 ± 1.63 60.6 ± 15.5
RVOe 741 71.0 ± 11.0 350 (47.23) 389 (52.50) 27.1 ± 4.3 0.49 ± 1.30 52.0 ± 22.7
 BRVOf 204 71.2 ± 10.0 85 (41.7) 119 (58.3) 27.1 ± 4.3 0.53 ± 1.37 55.9 ± 20.9
 CRVOg 121 70.3 ± 11.5 57 (47.1) 64 (52.9) 26.8 ± 4.4 0.32 ± 0.54 43.7 ± 25.0
  1. Further details for the OCEAN populations are provided in Additional file 1: Table S1, Additional file 3: Table S3, Additional file 4: Table S4, Additional file 5: Table S5, Additional file 6: Table S6, Additional file 7: Table S7
  2. a Time since diagnosis of primary indication until first injection in OCEAN study
  3. b Overall: Missing values: age: 25 patients; gender: 19; BMI: 413; time since diagnosis: 281; baseline VA: 47
  4. c nAMD: Missing values: age: 14 patients; gender: 11; BMI: 230; time since diagnosis: 199; baseline VA: 29
  5. d DME: Missing values: age: 9 patients; gender: 6; BMI: 87; time since diagnosis: 65; baseline VA: 8
  6. e RVO: Missing values: type of RVO (B/C): 416 patients; age: 2; gender: 2; BMI: 56; time since diagnosis: 17; baseline VA: 10
  7. f BRVO: Missing values: age and gender: 0 patients; BMI: 8; time since diagnosis: 3; baseline VA: 1
  8. g CRVO: Missing values: age and gender: 0 patients; BMI: 2; time since diagnosis: 3; baseline VA: 3
  9. Abbreviations: BMI: body mass index; BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; DME: diabetic macular oedema; ETDRS: Early Treatment Diabetic Retinopathy Study; N: total number of patients; n: number of patients; nAMD: neovascular age-related macular degeneration; RVO: retinal vein occlusion; SD: standard deviation; VA: visual acuity